Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Tirzepatide

Zepbound

Stage ApprovedStale

Sponsor Eli Lilly and Company

Route subcutaneous

Class GLP-1/GIP

Mechanism glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist

Target GIP receptor and GLP-1 receptor (TEC-0013)

Sources

fda, as of 2026-09-02Stale

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

ZEPBOUND (tirzepatide) Injection, for subcutaneous use. ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, published Sep 2, 2026, Study 1 ITT table

registry, as of 2025-07-24Stale

https://clinicaltrials.gov/study/NCT04184622

Protocol section, NCT04184622 SURMOUNT-1, last update posted 2025-07-24

registry, as of 2026-10-07Stale

https://clinicaltrials.gov/study/NCT05556512

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 15374. Conditions Obesity; Overweight. This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.

ClinicalTrials.gov NCT05556512 protocol and results modules

registry, as of 2026-03-19Stale

https://clinicaltrials.gov/study/NCT07481747

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1). Overall status RECRUITING. Phases PHASE3. Lead sponsor Hudson Biotech. Enrollment 2539. Conditions Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes w

ClinicalTrials.gov NCT07481747 protocol and results modules

registry, as of 2024-04-08Stale

https://clinicaltrials.gov/study/NCT04657003

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 938. Conditions Type 2 Diabetes; Overweight; Obesity. This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits). Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline Placebo 30.55 Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline 10 mg Tirzepatide 81.55 Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline 15 mg Tirzepatide 86.41 Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline Placebo 8.68 Percentage of Participants Who Achi

ClinicalTrials.gov NCT04657003 protocol and results modules

registry, as of 2026-05-12Stale

https://clinicaltrials.gov/study/NCT06914895

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 905. Conditions Type 1 Diabetes; Obesity; Overweight. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

ClinicalTrials.gov NCT06914895 protocol and results modules

registry, as of 2024-05-22Stale

https://clinicaltrials.gov/study/NCT04660643

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 783. Conditions Obesity; Overweight. This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which pa Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline Placebo 69.0 Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline Tirzepatide MTD 98.49 Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline Placebo 44.38 Percentage of Participants Who Achieve ≥

ClinicalTrials.gov NCT04660643 protocol and results modules

registry, as of 2025-08-20Stale

https://clinicaltrials.gov/study/NCT04847557

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 731. Conditions Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF). The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity. deaths Tirzepatide - MTD 19 diarrhoea Tirzepatide - MTD 65 nausea Tirzepatide - MTD 62 vomiting Tirzepatide - MTD 38 deaths Placebo 15 diarrhoea Placebo 23 nausea Placebo 23 vomiting Placebo 7

ClinicalTrials.gov NCT04847557 protocol and results modules

registry, as of 2024-05-16Stale

https://clinicaltrials.gov/study/NCT04657016

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 579. Conditions Obesity; Overweight. This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits). Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction Placebo 10.65 Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction Tirzepatide 94.37 Percentage of Participants Who Achieve ≥10%Body Weight Reduction Placebo 4.81 Percentage of Participants Who Achieve ≥10%Body Weight Reduction Tirzepatide 88.03 Percentage of Participants Who Achieve ≥15% Body We

ClinicalTrials.gov NCT04657016 protocol and results modules

registry, as of 2025-04-30Stale

https://clinicaltrials.gov/study/NCT05412004

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 469. Conditions Obstructive Sleep Apnea; Obesity. The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on P deaths Tirzepatide MTD_GPI1 0 diarrhoea Tirzepatide MTD_GPI1 30 nausea Tirzepatide MTD_GPI1 29 vomiting Tirzepatide MTD_GPI1 20 deaths Placebo_GPI1 0 diarrhoea Placebo_GPI1 15 nausea Placebo_GPI1 12 vomiting Placebo_GPI1 5 deaths Tirzepatide MTD_GPI2 0 diarrhoea Tirzepatide MTD_GPI2 26 nausea Tirzepatide MTD_GPI2 26 vomiting Tirzepatide MTD_GPI2 11

ClinicalTrials.gov NCT05412004 protocol and results modules

registry, as of 2026-02-17Stale

https://clinicaltrials.gov/study/NCT06962280

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 465. Conditions Type 1 Diabetes; Obesity; Overweight. The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.

ClinicalTrials.gov NCT06962280 protocol and results modules

registry, as of 2026-03-25Stale

https://clinicaltrials.gov/study/NCT06047548

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 441. Conditions Overweight; Obesity. The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.

ClinicalTrials.gov NCT06047548 protocol and results modules

registry, as of 2025-04-09Stale

https://clinicaltrials.gov/study/NCT06918405

Efficacy and Safety of Tirzepatide for Weight Management. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Chittagong Medical College. Enrollment 440. Conditions Obesity and Obesity-related Medical Conditions. The goal of this study is to learn if tirzepatide helps people manage their weight safely. It will include adults in Bangladesh who are overweight or obese, with or without type 2 diabetes. The main questions it aims to answer are: Does tirzepatide help people lose weight? What

ClinicalTrials.gov NCT06918405 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT06937086

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 350. Conditions Ulcerative Colitis; Obesity or Overweight. The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body wei

ClinicalTrials.gov NCT06937086 protocol and results modules

registry, as of 2026-09-24Stale

https://clinicaltrials.gov/study/NCT06439277

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2). Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 300. Conditions Obesity; Weight Gain. The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76

ClinicalTrials.gov NCT06439277 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT06937099

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 290. Conditions Crohn's Disease; Obesity or Overweight. The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of t

ClinicalTrials.gov NCT06937099 protocol and results modules

registry, as of 2026-06-17Stale

https://clinicaltrials.gov/study/NCT06588283

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 281. Conditions Psoriasis; Obesity. The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants s

ClinicalTrials.gov NCT06588283 protocol and results modules

registry, as of 2026-05-13Stale

https://clinicaltrials.gov/study/NCT06588296

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 279. Conditions Psoriatic Arthritis; Obesity. The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement i

ClinicalTrials.gov NCT06588296 protocol and results modules

registry, as of 2024-07-16Stale

https://clinicaltrials.gov/study/NCT04844918

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 267. Conditions Obesity. The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks. Percentage of Participants Who Achieve ≥5% Body Weight Reduction 10 mg Tirzepatide 94.37 Percentage of Participants Who Achieve ≥5% Body Weight Reduction 15 mg Tirzepatide 96.05 Percentage of Participants Who Achieve ≥5% Body Weight Reduction Placebo 20.0 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 10 mg Tirzepatide 85.92 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 15 mg Tirzepatide 92.11 Percentage of Pa

ClinicalTrials.gov NCT04844918 protocol and results modules

registry, as of 2026-11-02

https://clinicaltrials.gov/study/NCT07846865

Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea. Overall status NOT_YET_RECRUITING. Phases PHASE2,PHASE3. Lead sponsor Woolcock Institute of Medical Research. Enrollment 256. Conditions Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. When used, continuous positive airway pressure (CPAP) is an effective treatment for obstructive sleep apnea (OSA), a condition that is mainly caused by overweight and obesity. However, CPAP is plagued by poor adherence and high rates of discontinued use leaving most patients unde

ClinicalTrials.gov NCT07846865 protocol and results modules

registry, as of 2024-01-19Stale

https://clinicaltrials.gov/study/NCT05024032

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN). Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 210. Conditions Obesity; Overweight; Metabolism and Nutrition Disorder. This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight. Percentage of Participants Who Achieve ≥5% Body Weight Reduction 10 mg Tirzepatide 91.43 Percentage of Participants Who Achieve ≥5% Body Weight Reduction 15 mg Tirzepatide 92.65 Percentage of Participants Who Achieve ≥5% Body Weight Reduction Placebo 29.41 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 10 mg Tirzepatide 70.0 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 15 mg Tirze

ClinicalTrials.gov NCT05024032 protocol and results modules

registry, as of 2026-06-29Stale

https://clinicaltrials.gov/study/NCT06075667

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 160. Conditions Obesity; Overweight. The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have com

ClinicalTrials.gov NCT06075667 protocol and results modules

registry, as of 2026-11-04

https://clinicaltrials.gov/study/NCT07817875

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS). Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 150. Conditions Obesity. The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in t

ClinicalTrials.gov NCT07817875 protocol and results modules

registry, as of 2026-05-27Stale

https://clinicaltrials.gov/study/NCT07284511

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar. Overall status RECRUITING. Phases PHASE2,PHASE3. Lead sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre. Enrollment 105. Conditions Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus. This research study is testing whether a weekly medication called tirzepatide can help adults with type 1 diabetes use their insulin pump more easily, specifically by reducing or eliminating the need to count carbohydrates at meals. People with type 1 diabetes must take insulin

ClinicalTrials.gov NCT07284511 protocol and results modules

registry, as of 2026-09-18Stale

https://clinicaltrials.gov/study/NCT07829198

Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Universidade do Porto. Enrollment 70. Conditions Obesity. Many people who have bariatric (weight-loss) surgery do not lose as much weight as expected, or they regain weight over time. This study will test whether a medicine called tirzepatide can help these patients lose more weight and improve their overall health. Participants who ha

ClinicalTrials.gov NCT07829198 protocol and results modules

registry, as of 2026-08-03Stale

https://clinicaltrials.gov/study/NCT07738276

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Shahid Beheshti University of Medical Sciences. Enrollment 60. Conditions Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide. The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide. The main questions it aims to answer are: Does tirzepatide improve how far participants can

ClinicalTrials.gov NCT07738276 protocol and results modules

registry, as of 2026-08-04Stale

https://clinicaltrials.gov/study/NCT06162715

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2,PHASE3. Lead sponsor Vanderbilt University Medical Center. Enrollment 30. Conditions Severe Obesity; Obesity; BMI Greater Than 30. The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI \> 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirze

ClinicalTrials.gov NCT06162715 protocol and results modules

registry, as of 2026-05-06Stale

https://clinicaltrials.gov/study/NCT07298915

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor University of Virginia. Enrollment 24. Conditions Obesity & Overweight. This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with we

ClinicalTrials.gov NCT07298915 protocol and results modules

registry, as of 2026-10-07Stale

https://clinicaltrials.gov/study/NCT06143956

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 1481. Conditions Obesity; Overweight. The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entr

ClinicalTrials.gov NCT06143956 protocol and results modules

registry, as of 2026-03-23Stale

https://clinicaltrials.gov/study/NCT06037252

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 414. Conditions Type 2 Diabetes; Obesity. The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.

ClinicalTrials.gov NCT06037252 protocol and results modules

registry, as of 2026-05-06Stale

https://clinicaltrials.gov/study/NCT06373146

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 392. Conditions Obesity. The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

ClinicalTrials.gov NCT06373146 protocol and results modules

registry, as of 2026-04-13Stale

https://clinicaltrials.gov/study/NCT07521631

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes. Overall status RECRUITING. Phases PHASE2. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 372. Conditions Obesity. This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzep

ClinicalTrials.gov NCT07521631 protocol and results modules

registry, as of 2026-09-29Stale

https://clinicaltrials.gov/study/NCT06603571

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 367. Conditions Obesity; Overweight. The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabet

ClinicalTrials.gov NCT06603571 protocol and results modules

registry, as of 2026-04-15Stale

https://clinicaltrials.gov/study/NCT06326060

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 354. Conditions Obesity. This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a t

ClinicalTrials.gov NCT06326060 protocol and results modules

registry, as of 2026-09-09Stale

https://clinicaltrials.gov/study/NCT06965413

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Hoffmann-La Roche. Enrollment 285. Conditions Obesity; Overweight; Overweight With One Weight Related Comorbidity. The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity,

ClinicalTrials.gov NCT06965413 protocol and results modules

registry, as of 2026-05-26Stale

https://clinicaltrials.gov/study/NCT06643728

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 252. Conditions Obesity; Overweight. The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

ClinicalTrials.gov NCT06643728 protocol and results modules

registry, as of 2026-03-27Stale

https://clinicaltrials.gov/study/NCT06732245

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Biomed Industries, Inc.. Enrollment 224. Conditions Obesity and Overweight. A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women

ClinicalTrials.gov NCT06732245 protocol and results modules

registry, as of 2025-03-13Stale

https://clinicaltrials.gov/study/NCT06515418

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over. Overall status TERMINATED. Phases PHASE2. Lead sponsor BioAge Labs, Inc.. Enrollment 204. Conditions Obesity. This study aims to find out how well a combination of oral azelaprag taken once a day (QD) or twice a day (BID), along with a weekly injection of tirzepatide, works for weight management in adults 55 years and older. The researchers are also looking at safety. Estimated Study Le

ClinicalTrials.gov NCT06515418 protocol and results modules

registry, as of 2026-10-30Stale

https://clinicaltrials.gov/study/NCT06700538

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Arrowhead Pharmaceuticals. Enrollment 190. Conditions Obesity. This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the safety, tolerability, PK, and PD of multipl

ClinicalTrials.gov NCT06700538 protocol and results modules

registry, as of 2025-09-17Stale

https://clinicaltrials.gov/study/NCT07179120

Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor First Affiliated Hospital of Wenzhou Medical University. Enrollment 180. Conditions Obesity-related Male Infertility. Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semag

ClinicalTrials.gov NCT07179120 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07463846

A Study to Evaluate ALN-2232 in Participants With Obesity. Overall status RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Alnylam Pharmaceuticals. Enrollment 156. Conditions Obesity. The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232

ClinicalTrials.gov NCT07463846 protocol and results modules

registry, as of 2026-09-11Stale

https://clinicaltrials.gov/study/NCT05536804

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 134. Conditions Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D. We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.

ClinicalTrials.gov NCT05536804 protocol and results modules

Studies

SURMOUNT-1

Registry NCT04184622

Phase Phase 3

Status Completed

Enrollment 2539

Start 2019-12-04

Primary completion 2022-04-01

Study completion 2024-07-06

Placebo

Weeks 72

Population adults with obesity or overweight without type 2 diabetes

Estimand ITT

percent change from baseline in body weight, -3.1 %, week 72Stale

patients losing greater than or equal to 5% body weight, 34.5 %, week 72Stale

5 mg Tirzepatide

Dose 5 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population adults with obesity or overweight without type 2 diabetes

Estimand ITT

percent change from baseline in body weight, -15 %, week 72Stale

percent difference from placebo in body weight, -11.9 %, week 72, vs placeboStale

10 mg Tirzepatide

Dose 10 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population adults with obesity or overweight without type 2 diabetes

Estimand ITT

percent change from baseline in body weight, -19.5 %, week 72Stale

percent difference from placebo in body weight, -16.4 %, week 72, vs placeboStale

15 mg Tirzepatide

Dose 15 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population adults with obesity or overweight without type 2 diabetes

Estimand ITT

percent change from baseline in body weight, -20.9 %, week 72Stale

percent difference from placebo in body weight, -17.8 %, week 72, vs placeboStale

patients losing greater than or equal to 5% body weight, 90.9 %, week 72Stale

SURMOUNT-MMO

Registry NCT05556512

Phase Phase 3

Status Active, not recruiting

Enrollment 15374

Start 2022-10-11

Tirzepatide

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

SURMOUNT-1

Registry NCT07481747

Phase Phase 3

Status Recruiting

Enrollment 2539

Start 2026-02-02

Primary completion 2027-02-14

Study completion 2028-03-17

Catalyst Primary completion. 2027-02-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: Tirzepatide 5 mg once weekly + lifestyle intervention

Dose 5 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

Arm 2: Tirzepatide 10 mg once weekly + lifestyle intervention

Dose 10 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

Arm 3: Tirzepatide 15 mg once weekly + lifestyle intervention

Dose 15 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

Arm 4: Placebo once weekly + lifestyle intervention

Regimen once weekly

Weeks 72

Population Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

SURMOUNT-2

Registry NCT04657003

Phase Phase 3

Status Completed

Enrollment 938

Start 2021-03-29

Primary completion 2023-03-16

Study completion 2023-04-10

10 milligrams (mg) Tirzepatide

Regimen once weekly

Weeks 79

Comparator placebo

Population Type 2 Diabetes; Overweight; Obesity

15 mg Tirzepatide

Dose 15 mg

Regimen once weekly

Weeks 79

Comparator placebo

Population Type 2 Diabetes; Overweight; Obesity

participants with at least 5 percent body weight loss, 86.41 %, week 72Stale

participants with at least 10 percent body weight loss, 69.58 %, week 72Stale

participants with at least 15 percent body weight loss, 51.78 %, week 72Stale

participants with at least 20 percent body weight loss, 33.98 %, week 72Stale

deaths

participants with diarrhoea, 66 participantsStale

participants with nausea, 68 participantsStale

participants with vomiting, 40 participantsStale

Placebo

Regimen once weekly

Weeks 79

Population Type 2 Diabetes; Overweight; Obesity

participants with at least 5 percent body weight loss, 30.55 %, week 72Stale

participants with at least 10 percent body weight loss, 8.68 %, week 72Stale

participants with at least 15 percent body weight loss, 2.57 %, week 72Stale

participants with at least 20 percent body weight loss, 0.96 %, week 72Stale

deaths

participants with diarrhoea, 28 participantsStale

participants with nausea, 20 participantsStale

participants with vomiting, 10 participantsStale

10 mg Tirzepatide

Dose 10 mg

Regimen once weekly

Weeks 72

Population Type 2 Diabetes; Overweight; Obesity

participants with at least 5 percent body weight loss, 81.55 %, week 72Stale

participants with at least 10 percent body weight loss, 63.43 %, week 72Stale

participants with at least 15 percent body weight loss, 41.42 %, week 72Stale

participants with at least 20 percent body weight loss, 22.98 %, week 72Stale

deaths

participants with diarrhoea, 62 participantsStale

participants with nausea, 63 participantsStale

participants with vomiting, 34 participantsStale

SURPASS-T1D-1

Registry NCT06914895

Phase Phase 3

Status Active, not recruiting

Enrollment 905

Start 2025-04-25

Tirzepatide Dose 1

Regimen once weekly

Weeks 49

Comparator placebo

Population Type 1 Diabetes; Obesity; Overweight

Tirzepatide Dose 2

Regimen once weekly

Weeks 49

Comparator placebo

Population Type 1 Diabetes; Obesity; Overweight

Tirzepatide Dose 3

Regimen once weekly

Weeks 49

Comparator placebo

Population Type 1 Diabetes; Obesity; Overweight

Tirzepatide Dose 4

Regimen once weekly

Weeks 49

Comparator placebo

Population Type 1 Diabetes; Obesity; Overweight

Placebo

Regimen once weekly

Weeks 49

Population Type 1 Diabetes; Obesity; Overweight

SURMOUNT-4

Registry NCT04660643

Phase Phase 3

Status Completed

Enrollment 783

Start 2021-03-29

Primary completion 2023-04-25

Study completion 2023-05-18

Tirzepatide (lead-in)

Regimen every 4 weeks

Weeks 36

Comparator placebo

Population Obesity; Overweight

deaths

participants with diarrhoea, 165 participantsStale

participants with nausea, 278 participantsStale

participants with vomiting, 128 participantsStale

Tirzepatide MTD

Regimen once weekly

Weeks 36

Comparator placebo

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 98.49 %Stale

deaths

participants with diarrhoea, 36 participantsStale

participants with nausea, 27 participantsStale

participants with vomiting, 18 participantsStale

Placebo

Regimen weekly

Weeks 36

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 69 %Stale

deaths

participants with diarrhoea, 16 participantsStale

participants with nausea, 9 participantsStale

participants with vomiting, 4 participantsStale

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Registry NCT04847557

Phase Phase 3

Status Completed

Enrollment 731

Start 2021-04-20

Primary completion 2024-07-02

Study completion 2024-07-02

Tirzepatide

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF)

deaths

participants with diarrhoea, 65 participantsStale

participants with nausea, 62 participantsStale

participants with vomiting, 38 participantsStale

Placebo

Regimen once weekly

Weeks 4

Population Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF)

deaths

participants with diarrhoea, 23 participantsStale

participants with nausea, 23 participantsStale

participants with vomiting, 7 participantsStale

SURMOUNT-3

Registry NCT04657016

Phase Phase 3

Status Completed

Enrollment 579

Start 2021-03-29

Primary completion 2023-04-20

Study completion 2023-05-12

Tirzepatide

Regimen every 4 weeks

Weeks 72

Comparator placebo

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 94.37 %, week 72Stale

participants with at least 10 percent body weight loss, 88.03 %, week 72Stale

participants with at least 15 percent body weight loss, 73.94 %, week 72Stale

participants with at least 20 percent body weight loss, 54.93 %, week 72Stale

deaths

participants with diarrhoea, 89 participantsStale

participants with nausea, 114 participantsStale

participants with vomiting, 52 participantsStale

Placebo

Regimen once weekly

Weeks 72

Population Obesity; Overweight

participants with at least 5 percent body weight loss, 10.65 %, week 72Stale

participants with at least 10 percent body weight loss, 4.81 %, week 72Stale

participants with at least 15 percent body weight loss, 2.06 %, week 72Stale

participants with at least 20 percent body weight loss, 1.03 %, week 72Stale

deaths

participants with diarrhoea, 27 participantsStale

participants with nausea, 41 participantsStale

participants with vomiting, 4 participantsStale

SURMOUNT-OSA

Registry NCT05412004

EudraCT 2021-004552-41

Phase Phase 3

Status Completed

Enrollment 469

Start 2022-06-21

Primary completion 2024-03-12

Study completion 2024-03-29

Tirzepatide MTD_GPI1

Regimen once weekly

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea; Obesity

deaths

participants with diarrhoea, 30 participantsStale

participants with nausea, 29 participantsStale

participants with vomiting, 20 participantsStale

Placebo_GPI1

Regimen once weekly

Weeks 52

Population Obstructive Sleep Apnea; Obesity

deaths

participants with diarrhoea, 15 participantsStale

participants with nausea, 12 participantsStale

participants with vomiting, 5 participantsStale

Tirzepatide MTD_GPI2

Regimen every 4 weeks

Weeks 52

Comparator placebo

Population Obstructive Sleep Apnea; Obesity

deaths

participants with diarrhoea, 26 participantsStale

participants with nausea, 26 participantsStale

participants with vomiting, 11 participantsStale

Placebo_GPI2

Regimen once weekly

Weeks 52

Population Obstructive Sleep Apnea; Obesity

deaths

participants with diarrhoea, 10 participantsStale

participants with nausea, 6 participantsStale

participants with vomiting, 1 participantsStale

SURPASS-T1D-2

Registry NCT06962280

Phase Phase 3

Status Active, not recruiting

Enrollment 465

Start 2025-05-12

Tirzepatide

Regimen once weekly

Comparator placebo

Population Type 1 Diabetes; Obesity; Overweight

Placebo

Regimen once weekly

Population Type 1 Diabetes; Obesity; Overweight

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Registry NCT06047548

Phase Phase 3

Status Completed

Enrollment 441

Start 2023-09-20

Primary completion 2026-01-20

Study completion 2026-01-20

Catalyst Primary completion. 2026-01-20. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide 5 milligram (mg)

Regimen once weekly

Comparator placebo

Population Overweight; Obesity

Tirzepatide Maximum Tolerated Dose

Regimen once weekly

Comparator placebo

Population Overweight; Obesity

Placebo

Regimen once weekly

Population Overweight; Obesity

Efficacy and Safety of Tirzepatide for Weight Management

Registry NCT06918405

Phase Phase 3

Status Active, not recruiting

Enrollment 440

Start 2025-01-01

Primary completion 2026-06-30

Study completion 2026-06-30

Catalyst Primary completion. 2026-06-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide arm

Regimen once weekly

Weeks 52

Population Obesity and Obesity-related Medical Conditions

COMMIT-UC

Registry NCT06937086

Phase Phase 3

Status Recruiting

Enrollment 350

Start 2025-06-26

Mirikizumab + Tirzepatide

Comparator placebo

Population Ulcerative Colitis; Obesity or Overweight

Mirikizumab + Placebo

Population Ulcerative Colitis; Obesity or Overweight

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Registry NCT06439277

Phase Phase 3

Status Recruiting

Enrollment 300

Start 2024-06-03

Tirzepatide

Regimen once weekly

Weeks 76

Comparator placebo

Population Obesity; Weight Gain

Placebo

Regimen once weekly

Weeks 76

Population Obesity; Weight Gain

COMMIT-CD

Registry NCT06937099

Phase Phase 3

Status Recruiting

Enrollment 290

Start 2025-06-26

Mirikizumab + Tirzepatide

Comparator placebo

Population Crohn's Disease; Obesity or Overweight

Mirikizumab + Placebo

Population Crohn's Disease; Obesity or Overweight

TOGETHER-PsO

Registry NCT06588283

Phase Phase 3

Status Completed

Enrollment 281

Start 2024-09-30

Primary completion 2026-01-08

Study completion 2026-06-01

Catalyst Primary completion. 2026-01-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Ixekizumab

Population Psoriasis; Obesity

Ixekizumab and Tirzepatide

Population Psoriasis; Obesity

TOGETHER-PsA

Registry NCT06588296

Phase Phase 3

Status Completed

Enrollment 279

Start 2024-09-24

Primary completion 2025-11-18

Study completion 2026-04-23

Catalyst Primary completion. 2025-11-18. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Ixekizumab

Population Psoriatic Arthritis; Obesity

Ixekizumab and Tirzepatide

Population Psoriatic Arthritis; Obesity

SURMOUNT-J

Registry NCT04844918

Phase Phase 3

Status Completed

Enrollment 267

Start 2021-05-10

Primary completion 2023-06-24

Study completion 2023-06-24

10 Milligrams (mg) Tirzepatide

Regimen once weekly

Weeks 72

Comparator placebo

Population Obesity

15 mg Tirzepatide

Dose 15 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population Obesity

participants with at least 5 percent body weight loss, 96.05 %, week 72Stale

participants with at least 10 percent body weight loss, 92.11 %, week 72Stale

participants with at least 15 percent body weight loss, 82.89 %, week 72Stale

deaths

participants with diarrhoea, 7 participantsStale

participants with nausea, 18 participantsStale

participants with vomiting, 9 participantsStale

Placebo

Regimen once weekly

Weeks 72

Population Obesity

participants with at least 5 percent body weight loss, 20 %, week 72Stale

participants with at least 10 percent body weight loss, 4 %, week 72Stale

participants with at least 15 percent body weight loss, 1.33 %, week 72Stale

deaths

participants with diarrhoea, 3 participantsStale

participants with nausea, 3 participantsStale

participants with vomiting, 3 participantsStale

10 mg Tirzepatide

Dose 10 mg

Regimen once weekly

Weeks 72

Population Obesity

participants with at least 5 percent body weight loss, 94.37 %, week 72Stale

participants with at least 10 percent body weight loss, 85.92 %, week 72Stale

participants with at least 15 percent body weight loss, 63.38 %, week 72Stale

deaths

participants with diarrhoea, 9 participantsStale

participants with nausea, 10 participantsStale

participants with vomiting, 5 participantsStale

TIRZE-PAP

Registry NCT07846865

Phase Phase 2/3

Status Not yet recruiting

Enrollment 256

Start 2026-10-01

Primary completion 2028-12-01

Study completion 2028-12-01

Catalyst Primary completion. 2028-12-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Continuous Positive Airway Pressure (CPAP)

Regimen once weekly

Weeks 4

Population Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive

Tirzepatide

Regimen once weekly

Weeks 4

Population Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive

SURMOUNT-CN

Registry NCT05024032

Phase Phase 3

Status Completed

Enrollment 210

Start 2021-09-01

Primary completion 2022-12-27

Study completion 2022-12-27

10 Milligrams (mg) Tirzepatide

Regimen once weekly

Comparator placebo

Population Obesity; Overweight; Metabolism and Nutrition Disorder

15 mg Tirzepatide

Dose 15 mg

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity; Overweight; Metabolism and Nutrition Disorder

participants with at least 5 percent body weight loss, 92.65 %, week 52Stale

participants with at least 10 percent body weight loss, 83.82 %, week 52Stale

participants with at least 15 percent body weight loss, 72.06 %, week 52Stale

deaths

participants with diarrhoea, 29 participantsStale

participants with nausea, 23 participantsStale

participants with vomiting, 14 participantsStale

Placebo

Regimen once weekly

Weeks 52

Population Obesity; Overweight; Metabolism and Nutrition Disorder

participants with at least 5 percent body weight loss, 29.41 %, week 52Stale

participants with at least 10 percent body weight loss, 14.71 %, week 52Stale

participants with at least 15 percent body weight loss, 2.94 %, week 52Stale

deaths

participants with diarrhoea, 6 participantsStale

participants with nausea, 4 participantsStale

participants with vomiting, 3 participantsStale

10 mg Tirzepatide

Dose 10 mg

Regimen once weekly

Weeks 52

Population Obesity; Overweight; Metabolism and Nutrition Disorder

participants with at least 5 percent body weight loss, 91.43 %, week 52Stale

participants with at least 10 percent body weight loss, 70 %, week 52Stale

participants with at least 15 percent body weight loss, 48.57 %, week 52Stale

deaths

participants with diarrhoea, 28 participantsStale

participants with nausea, 21 participantsStale

participants with vomiting, 8 participantsStale

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Registry NCT06075667

Phase Phase 3

Status Active, not recruiting

Enrollment 160

Start 2023-10-16

Primary completion 2026-06-02

Catalyst Primary completion. 2026-06-02. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide

Regimen once weekly

Weeks 90

Comparator placebo

Population Obesity; Overweight

Placebo

Regimen once weekly

Weeks 90

Population Obesity; Overweight

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURM

Registry NCT07817875

Phase Phase 3

Status Recruiting

Enrollment 150

Start 2026-09-25

Tirzepatide

Regimen once weekly

Weeks 104

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 104

Population Obesity

TZP

Registry NCT07284511

Phase Phase 2/3

Status Recruiting

Enrollment 105

Start 2026-05-19

Tirzepatide group

Regimen once weekly

Weeks 1

Population Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus

Control group

Regimen once weekly

Weeks 1

Population Type 1 Diabetes; Type 1 Diabetes Mellitus; T1D; T1DM; T1DM - Type 1 Diabetes Mellitus

TirBaS

Registry NCT07829198

Phase Phase 3

Status Not yet recruiting

Enrollment 70

Tirzepatide

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 52

Population Obesity

DUAL-HFrEF

Registry NCT07738276

Phase Phase 3

Status Not yet recruiting

Enrollment 60

Start 2026-07-18

Primary completion 2027-06-11

Study completion 2027-12-22

Catalyst Primary completion. 2027-06-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide

Regimen once weekly

Weeks 4

Comparator placebo

Population Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide

Placebo

Regimen once weekly

Weeks 4

Population Heart Failure and Reduced Ejection Fraction; Obesity & Overweight; Tirzepatide

GRABS-0

Registry NCT06162715

Phase Phase 2/3

Status Active, not recruiting

Enrollment 30

Start 2024-10-30

Primary completion 2027-01-01

Study completion 2027-12-01

Catalyst Primary completion. 2027-01-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide Group

Regimen every 4 weeks

Weeks 24

Population Severe Obesity; Obesity; BMI Greater Than 30

Control - Standard of care Post-Gastric Bypass Surgery

Regimen every 4 weeks

Weeks 24

Population Severe Obesity; Obesity; BMI Greater Than 30

EXER-MED

Registry NCT07298915

Phase Phase 3

Status Not yet recruiting

Enrollment 24

Exercise

Regimen once monthly

Weeks 16

Population Obesity & Overweight

Standard Care

Regimen once monthly

Weeks 16

Population Obesity & Overweight

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Registry NCT06143956

Phase Phase 2

Status Recruiting

Enrollment 1481

Start 2023-11-17

LY3305677 Obesity ISA OXA1

Population Obesity; Overweight

LY3841136 Obesity ISA LAA1

Population Obesity; Overweight

LY3841136 Obesity ISA LAA2

Population Obesity; Overweight

LY3549492 Obesity ISA GN01

Population Obesity; Overweight

LY3549492 Obesity ISA GN02

Population Obesity; Overweight

Obesity ISA MC01

Population Obesity; Overweight

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Registry NCT06037252

Phase Phase 2

Status Active, not recruiting

Enrollment 414

Start 2023-09-21

Primary completion 2026-01-08

Catalyst Primary completion. 2026-01-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide High Dose 1

Comparator placebo

Population Type 2 Diabetes; Obesity

Tirzepatide High Dose 2

Comparator placebo

Population Type 2 Diabetes; Obesity

Tirzepatide

Comparator placebo

Population Type 2 Diabetes; Obesity

Placebo

Population Type 2 Diabetes; Obesity

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Registry NCT06373146

Phase Phase 2

Status Completed

Enrollment 392

Start 2024-04-24

Primary completion 2025-12-15

Study completion 2026-04-02

Catalyst Primary completion. 2025-12-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

TZP + Mibavademab-placebo (MIBA-PBO) [Group B]

Regimen once weekly

Weeks 24

Population Obesity

TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]

Regimen once weekly

Weeks 24

Population Obesity

TZP + MIBA [Group D]

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

TZP + MIBA-PBO [Group E]

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

TZP + MIBA-PBO then TZP + MIBA [Group G]

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

Registry NCT07521631

Phase Phase 2

Status Recruiting

Enrollment 372

Start 2026-03-31

Primary completion 2027-02-04

Study completion 2027-07-23

Catalyst Primary completion. 2027-02-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HDM1005 injection dose group 1

Regimen once weekly

Weeks 52

Population Obesity

HDM1005 injection dose group 2

Regimen once weekly

Weeks 52

Population Obesity

HDM1005 injection dose group 3

Regimen once weekly

Weeks 52

Population Obesity

tirzepatide injection

Regimen once weekly

Weeks 52

Population Obesity

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Registry NCT06603571

Phase Phase 2

Status Completed

Enrollment 367

Start 2024-09-20

Primary completion 2026-07-01

Study completion 2026-09-14

Catalyst Primary completion. 2026-07-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

LY3841136 Dose 1

Comparator placebo

Population Obesity; Overweight

LY3841136 Dose 2

Comparator placebo

Population Obesity; Overweight

LY3841136 Dose 3

Comparator placebo

Population Obesity; Overweight

LY3841136 Dose 1 + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

LY3841136 Dose 2 + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

LY3841136 Dose 2 + Tirzepatide Dose 2

Comparator placebo

Population Obesity; Overweight

LY3841136 Dose 3 + Tirzepatide Dose 3

Comparator placebo

Population Obesity; Overweight

Tirzepatide Dose 3

Comparator placebo

Population Obesity; Overweight

LY3841136 Dose 2 + Tirzepatide Dose 3

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

Registry NCT06326060

Phase Phase 2

Status Completed

Enrollment 354

Start 2024-03-18

Primary completion 2025-04-10

Study completion 2025-05-01

Catalyst Primary completion. 2025-04-10. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Dosing scheme a: NNC0519-0130

Regimen once weekly

Weeks 42

Comparator placebo

Population Obesity

Dosing scheme a: Placebo

Regimen once weekly

Weeks 42

Population Obesity

Dosing scheme b: NNC0519-0130

Regimen once weekly

Weeks 42

Comparator placebo

Population Obesity

Dosing scheme b: Placebo

Regimen once weekly

Weeks 42

Population Obesity

Dosing scheme c: NNC0519-0130

Regimen once weekly

Weeks 42

Comparator placebo

Population Obesity

Dosing scheme c: Placebo

Regimen once weekly

Weeks 42

Population Obesity

Dosing scheme d: NNC0519-0130

Regimen once weekly

Weeks 42

Comparator placebo

Population Obesity

Dosing scheme d: Placebo

Regimen once weekly

Weeks 42

Population Obesity

Dosing scheme e: NNC0519-0130

Regimen once weekly

Weeks 42

Comparator placebo

Population Obesity

Dosing scheme e: Placebo

Regimen once weekly

Weeks 42

Population Obesity

Dosing scheme f: NNC0519-0130

Regimen once weekly

Weeks 42

Comparator placebo

Population Obesity

Dosing scheme f: Placebo

Regimen once weekly

Weeks 42

Population Obesity

Dosing scheme g: Tirzepatide

Regimen once weekly

Weeks 42

Comparator placebo

Population Obesity

GYMINDA

Registry NCT06965413

Phase Phase 2

Status Active, not recruiting

Enrollment 285

Start 2025-05-05

Primary completion 2026-09-03

Study completion 2027-03-31

Catalyst Primary completion. 2026-09-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo + Tirzepatide

Regimen every 4 weeks

Weeks 48

Population Obesity; Overweight; Overweight With One Weight Related Comorbidity

RO7204239 low dose + Tirzepatide

Regimen every 4 weeks

Weeks 48

Comparator placebo

Population Obesity; Overweight; Overweight With One Weight Related Comorbidity

RO7204239 medium dose + Tirzepatide

Regimen every 4 weeks

Weeks 48

Comparator placebo

Population Obesity; Overweight; Overweight With One Weight Related Comorbidity

RO7204239 high dose + Tirzepatide

Regimen every 4 weeks

Weeks 48

Comparator placebo

Population Obesity; Overweight; Overweight With One Weight Related Comorbidity

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Registry NCT06643728

Phase Phase 2

Status Active, not recruiting

Enrollment 252

Start 2024-10-21

Primary completion 2026-01-16

Catalyst Primary completion. 2026-01-16. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part A: Bimagrumab Dose 2 + Tirzepatide Placebo

Population Obesity; Overweight

Part A: Bimagrumab Placebo + Tirzepatide Dose 1

Population Obesity; Overweight

Part A: Bimagrumab Placebo + Tirzepatide Dose 2

Population Obesity; Overweight

Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2

Comparator placebo

Population Obesity; Overweight

Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2

Comparator placebo

Population Obesity; Overweight

Part A: Bimagrumab Placebo + Tirzepatide Placebo

Population Obesity; Overweight

Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1

Comparator placebo

Population Obesity; Overweight

Part B: Bimagrumab Dose 1 + Tirzepatide Placebo

Population Obesity; Overweight

Part B: Bimagrumab Placebo + Tirzepatide Placebo

Population Obesity; Overweight

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Registry NCT06732245

Phase Phase 2

Status Not yet recruiting

Enrollment 224

Start 2026-08-15

Primary completion 2027-08-15

Study completion 2027-12-15

Catalyst Primary completion. 2027-08-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo Comparator: Placebo

Regimen daily

Weeks 4

Population Obesity and Overweight

Placebo + Tirzepatide 5 mg

Dose 5 mg

Regimen weekly

Weeks 4

Population Obesity and Overweight

Placebo + Tirzepatide 10 mg

Dose 10 mg

Regimen weekly

Weeks 4

Population Obesity and Overweight

NA-931 60mg to NA-931 150 mg + no Tirzepatide

Dose 150 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity and Overweight

NA-931 60 mg + Tirzepatide 5 mg

Dose 5 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity and Overweight

NA-931 120 mg + Tirzepatide 5 mg

Dose 5 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity and Overweight

NA-931 150 mg + no Tirzepatide

Dose 150 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity and Overweight

NA-931 150 mg + Tirzepatide 2.5 mg

Dose 2.5 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity and Overweight

NA-931 150 mg + Tirzepatide 5 mg

Dose 5 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity and Overweight

STRIDES

Registry NCT06515418

Phase Phase 2

Status Terminated

Enrollment 204

Start 2024-06-27

Primary completion 2025-02-06

Study completion 2025-02-12

Catalyst Primary completion. 2025-02-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

A: Tirzepatide Monotherapy

Regimen once weekly

Weeks 48

Population Obesity

B: Azelaprag once daily plus Tirzepatide

Regimen once weekly

Weeks 48

Population Obesity

C: Azelaprag twice daily plus Tirzepatide

Regimen once weekly

Weeks 48

Population Obesity

D: Azelaprag Monotherapy

Regimen once weekly

Weeks 48

Population Obesity

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Registry NCT06700538

Phase Phase 1/2

Status Active, not recruiting

Enrollment 190

Start 2024-12-04

Primary completion 2027-10-15

Study completion 2028-02-15

Catalyst Primary completion. 2027-10-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part 1: ARO-INHBE

Regimen weekly

Comparator placebo

Population Obesity

Part 1: Placebo

Regimen weekly

Population Obesity

Part 2: ARO-INHBE + Tirzepatide

Regimen weekly

Comparator placebo

Population Obesity

Part 2: Placebo + Tirzepatide

Regimen weekly

Population Obesity

Part 3: ARO-INHBE

Regimen weekly

Comparator placebo

Population Obesity

Part 3: Placebo

Regimen weekly

Population Obesity

Part 3: ARO-INHBE + Tirzepatide

Regimen weekly

Comparator placebo

Population Obesity

Part 3: Placebo + Tirzepatide

Regimen weekly

Population Obesity

Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

Registry NCT07179120

Phase Phase 2

Status Not yet recruiting

Enrollment 180

Start 2026-05-01

Primary completion 2026-08-12

Study completion 2027-01-02

Catalyst Primary completion. 2026-08-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide Injection Therapy (Intervention A Group)

Regimen weekly

Weeks 1

Population Obesity-related Male Infertility

Tirzepatide Injection Therapy (Intervention B Group)

Regimen weekly

Weeks 1

Population Obesity-related Male Infertility

Lifestyle Modification Management (Control Group)

Regimen weekly

Weeks 1

Population Obesity-related Male Infertility

A Study to Evaluate ALN-2232 in Participants With Obesity

Registry NCT07463846

Phase Phase 1/2

Status Recruiting

Enrollment 156

Start 2026-03-02

Primary completion 2027-04-28

Study completion 2028-04-28

Catalyst Primary completion. 2027-04-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part A: ALN-2232

Regimen once weekly

Comparator placebo

Population Obesity

Part A: Placebo

Regimen once weekly

Population Obesity

Part B: ALN-2232

Regimen once weekly

Comparator placebo

Population Obesity

Part B: Placebo

Regimen once weekly

Population Obesity

Part C: ALN-2232

Regimen once weekly

Comparator placebo

Population Obesity

Part C: Placebo

Regimen once weekly

Population Obesity

Part C: Tirzepatide

Regimen once weekly

Comparator placebo

Population Obesity

TREASURE-CKD

Registry NCT05536804

EudraCT 2021-005273-47

Phase Phase 2

Status Completed

Enrollment 134

Start 2023-02-08

Primary completion 2026-07-06

Study completion 2026-07-30

Catalyst Primary completion. 2026-07-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Tirzepatide

Comparator placebo

Population Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D

Placebo

Population Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D